This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Because of the rarity of this disease type, this is a "just in time" study. This means that once a patient is identified and the CRA is informed, it will go through the regulatory process and may take up to 10 days to be approved for use.
- Patricia Kulla, 314-996-4617
View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.